Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119195 | 1.00 | CASP3 (0.58) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL14024234 | 0.89 | CASP3 (0.59) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL119762 | 0.89 | CASP3 (0.61) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL3201847 | 0.89 | CASP3 (0.61) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29401028 | 0.89 | CASP3 (0.61) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL31045969 | 0.89 | CASP3 (0.61) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL119533 | 0.89 | CASP3 (0.61) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29400949 | 0.88 | CASP3 (0.49) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL377860 | 0.88 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL25262884 | 0.85 | CASP3 (0.59) | CASP3KMT2AMDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410028-B2 | Methods for synthesis of encoded libraries | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410028-B2 | Methods for synthesis of encoded libraries | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120245040-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | GLAXOSMITHKLINE (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245040-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | GLAXOSMITHKLINE (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120071329-A1 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | GLAXOSMITHKLINE (US) | 2011-10-13 | — | — | US | disclosed |
| US-7989395-B2 | Methods for identifying compounds of interest using encoded libraries | GLAXOSMITHKLINE LLC (US) | 2011-08-02 | — | — | US | disclosed |
| US-7972992-B2 | Solid phase synthesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7972992-B2 | Solid phase synthesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7972994-B2 | Methods for synthesis of encoded libraries | GLAXOSMITHKLINE LLC (US) | 2011-07-05 | — | — | US | disclosed |
| US-7972994-B2 | Methods for synthesis of encoded libraries | GLAXOSMITHKLINE LLC (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110136697-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| US-7935658-B2 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935658-B2 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090062147-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062147-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2009-03-05 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245040-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | RNGTT, DTYMK, DUT | CASP3 4851/4885KMT2A 1848/4885MDM4 1148/4885 |
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | RNGTT, DTYMK, DUT | CASP3 4851/4885KMT2A 1848/4885MDM4 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.